Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA)
Status: Recruiting
Location: See all (13) locations...
Study Type: Observational
SUMMARY
Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Healthy Volunteers: f
View:
• Male or female, ages ≥6 years at the time of signing the informed consent (and assent, if applicable).
• Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles or compound heterozygous), with onset of FA occurring at ≤25 years of age
• Confirmed left ventricular hypertrophy (LVH)
• Left ventricular ejection fraction ≥40%
Locations
United States
California
University of California San Diego
RECRUITING
La Jolla
Florida
University of South Florida
RECRUITING
Tampa
Indiana
Indiana University - Riley Children's Health
RECRUITING
Indianapolis
Massachusetts
Boston Children's Hospital
RECRUITING
Boston
Minnesota
Mayo Clinic
RECRUITING
Rochester
Missouri
Washington University School of Medicine in St. Louis
RECRUITING
St Louis
Ohio
Cincinnati Children's Hospital
RECRUITING
Cincinnati
Other Locations
Brazil
Campinas State University (UNICAMP)
RECRUITING
Campinas
Instituto D'or de Pesquisa e Ensino - Hospital São Rafael
RECRUITING
Salvador
Canada
Centre Hospitalier de Universite de Montreal (CHUM)
RECRUITING
Montreal
France
Institut de Cardiologie Hopital Pitie Salpetriere
RECRUITING
Paris
Germany
University Hospital Tübingen
RECRUITING
Tübingen
Spain
Hospital Univeritario Puerta de Hierro de Majadahonda
RECRUITING
Majadahonda
Contact Information
Primary
Lexeo Clinical Trials
clinicaltrials@lexeotx.com
212-547-9879
Time Frame
Start Date: 2025-09-30
Estimated Completion Date: 2027-09
Participants
Target number of participants: 65
Treatments
Cohort 1: Participants ≥16 years of age with FA-CM
Participants ≥16 years of age with FA-CM
Cohort 2: Participants ≥6 to <16 years of age with FA-CM
Participants ≥6 to \<16 years of age with FA-CM
Related Therapeutic Areas
Sponsors
Leads: Lexeo Therapeutics